<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01522794</url>
  </required_header>
  <id_info>
    <org_study_id>SNOXH94C101</org_study_id>
    <secondary_id>2011-005022-22</secondary_id>
    <nct_id>NCT01522794</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics/Pharmacodynamics of NOX-H94 in the Human Endotoxemia Model</brief_title>
  <official_title>Randomized Double Blind Placebo Controlled PK/PD Study on the Effects of a Single Intravenous Dose of NOX-H94 on Serum Iron During Experimental Human Endotoxemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NOXXON Pharma AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NOXXON Pharma AG</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the effect of the anti-hepcidin Spiegelmer NOX-H94 on
      iron homeostasis during systemic inflammation induced by endotoxin.

      In the human endotoxemia model, intravenously administered lipopolysaccharide elicits an
      inflammatory response with release of pro-inflammatory cytokines, such as IL-6 and TNF-alfa,
      with subsequent induction of hepcidin. As a consequence of hepcidin induction, serum iron
      concentrations decrease.

      This study in healthy subjects investigates the capacity of NOX-H94 to inactivate hepcidin
      and to prevent serum iron decrease in a pathophysiological model prior to studying the
      efficacy of NOX-H94 in patients with anemia of chronic disease.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2012</start_date>
  <completion_date type="Actual">April 2012</completion_date>
  <primary_completion_date type="Actual">March 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>serum iron</measure>
    <time_frame>9 hours</time_frame>
    <description>Change versus baseline; comparison of subjects treated with NOX-H94 versus placebo</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics: Effects of NOX-H94 on Iron homeostasis</measure>
    <time_frame>up to 2 Weeks</time_frame>
    <description>Change from baseline and group comparison (NOX-H94 vs. placebo) of:
serum iron, transferrin saturation, ferritin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic profile of NOX-H94</measure>
    <time_frame>12 time points over 2 Weeks</time_frame>
    <description>plasma concentration-time profile T0 to 2 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability</measure>
    <time_frame>up to 2 Weeks</time_frame>
    <description>Safety and tolerability parameters will be evaluated along the entire study duration consisting of spontaneously reported adverse events, physical examination and vital signs, hematology and clinical chemistry laboratory examinations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effects of NOX-H94 on innate immune response</measure>
    <time_frame>up to 2 weeks</time_frame>
    <description>To assess the effect of a single dose administration of NOX H94 on the innate immune response during experimental endotoxemia: TNF-α, IL-6, IL-1RA, IL-10</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Cmax of NOX-H94</measure>
    <time_frame>Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: AUC of NOX-H94</measure>
    <time_frame>0-2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Clearance of NOX-H94</measure>
    <time_frame>0-2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics: effect of NOX-H94 on Red blood cell parameters</measure>
    <time_frame>0- 2 weeks</time_frame>
    <description>Change versus baseline and group comparison: reticulocyte hemoglobin content, hemoglobin, mean cell volume, mean cell hemoglobin</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Anemia of Chronic Disease</condition>
  <arm_group>
    <arm_group_label>NOX-H94</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of NOX-H94</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single dose of placebo control</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NOX-H94</intervention_name>
    <description>single i.v. infusion</description>
    <arm_group_label>NOX-H94</arm_group_label>
    <other_name>lexaptepid pegol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo solution</intervention_name>
    <description>single i.v. infusion</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Main Inclusion Criteria:

          -  BMI between 18 and 30 kg/m², with a lower limit of body weight of 50 kg

          -  Healthy as determined by medical history, physical examination, vital signs, 12 lead
             electrocardiogram, and clinical laboratory parameters

          -  Serum iron and red blood parameters Hb, MCV, ferritin, serum iron, and total iron
             binding capacity within reference range

        Main Exclusion Criteria:

          -  Use of any medication, recreational drugs or anti-oxidant vitamin supplements within 7
             days

          -  Use of caffeine, nicotine, or alcohol within 1 day

          -  Previous participation in a trial where LPS was administered

          -  Surgery or trauma with significant blood loss or blood donation within 3 months

          -  History, signs or symptoms of cardiovascular disease (vaso-vagal collapse or of
             orthostatic hypotension, Resting pulse rate ≤45 or ≥100/min, Hypertension,
             Hypotension, ECG conduction abnormalities)

          -  Renal impairment: plasma creatinine &gt;120 µmol/L

          -  Liver function tests (alkaline phosphatase, AST, ALT and γ-GT) outside of the
             reference range or total bilirubin &gt;20 µmol/L

          -  Hemoglobin or iron parameters (iron, transferring saturation, ferritin) outside of the
             reference ranges

          -  History of asthma

          -  Immuno-deficiency

          -  Positive test of HIV type 1/2 antibodies, HBs antigen, HBc antibodies and HCV
             antibodies unless antibody titer is induced by vaccination

          -  CRP &gt; reference range or clinically significant acute illness, including infections,
             within 2 weeks

          -  Treatment with investigational drugs or participation in any other clinical trial
             within 30 days prior to study drug administration

          -  Known or suspected of not being able to comply with the trial protocol

          -  Inability to personally provide written informed consent and/or take part in the study
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kai Riecke, MD</last_name>
    <role>Study Director</role>
    <affiliation>NOXXON Pharma AG</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Peter Pickkers, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Radboud University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Radboud University Nijmegen Medical Centre</name>
      <address>
        <city>Nijmegen</city>
        <zip>6500 HB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <link>
    <url>http://bloodjournal.hematologylibrary.org/content/106/5/1864.long</url>
    <description>Literature: Kemna et. al. 2005</description>
  </link>
  <link>
    <url>https://ash.confex.com/ash/2012/webprogram/Paper50672.html</url>
    <description>Result summary: Abstract 3452, ASH 2012</description>
  </link>
  <link>
    <url>http://dx.doi.org/10.1182/blood-2014-03-559484</url>
    <description>Publication of clinical trial (open access)</description>
  </link>
  <verification_date>November 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 18, 2012</study_first_submitted>
  <study_first_submitted_qc>January 27, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 1, 2012</study_first_posted>
  <last_update_submitted>November 7, 2014</last_update_submitted>
  <last_update_submitted_qc>November 7, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 10, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chronic Disease</mesh_term>
    <mesh_term>Endotoxemia</mesh_term>
    <mesh_term>Anemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

